{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018810","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.261276+00:00","generated_at":"2026-06-15T13:05:52.800924+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Annexon reports Q1 net loss $38.7M; pipeline milestones expected through 2024","bullets":["Net loss $38.7M ($0.52/sh) vs $35.4M ($0.92/sh) in Q1 2022; R&D spend rose to $32.3M.","Cash and investments $228.2M; runway into 2025 for ongoing trials.","Phase 2 ARCHER trial of ANX007 in geographic atrophy data expected mid-2023.","Phase 3 GBS trial enrollment completion 2H'23; topline results 1H'24.","Initial Phase 1b data for ANX009 in lupus nephritis due 1H'23; ANX1502 oral data 2H'23."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018810","json":"https://secwatch.observer/filing/0000950170-23-018810.json","markdown":"https://secwatch.observer/filing/0000950170-23-018810.md","text":"https://secwatch.observer/filing/0000950170-23-018810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000095017023018810/0000950170-23-018810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000095017023018810/annx-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:05:52.800924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd283eae5a5ea4d408ba3e2d7899b57080c8ad76","claim":"Annexon, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss was $38.7 million or $0.52 per share.","evidence_excerpt":"On May 8, 2023, Annexon, Inc. (the “Company”) announced certain financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528115/000095017023018810/0000950170-23-018810-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $38.7 million or $0.52 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}